跳至主要内容
临床试验/IRCT20240302061146N1
IRCT20240302061146N1招募中2 期

Investigating the effect of adding octreotide to indomethacin compared to indomethacin alone in preventing pancreatitis after ERCP in high-risk patients: a randomized clinical trial

Mashhad University of Medical Sciences0 个研究点目标入组 88 人开始时间: 待定最近更新:
适应症

试验速览

阶段
2 期
状态
招募中
入组人数
88

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 75 years(—)
性别
All

入选标准

  • Participants aged between 18 and 75 years
  • Participants with normal levels of amylase and lipase before undergoing Endoscopic Retrograde Cholangiopancreatography (ERCP).
  • Presence of high-risk criteria for post-ERCP pancreatitis based on UpToDate recommendations
  • Multiple cannulations during ERCP
  • History of previous pancreatitis following ERCP
  • Dysfunction of type one and two sphincter of Oddi
  • Repeated injection of contrast material or other fluids into the main pancreatic duct
  • Balloon dilation of an intact biliary sphincter
  • Pancreatic sphincterotomy.

排除标准

  • Pregnancy or breastfeeding
  • Known hypersensitivity to somatostatin
  • Liver or kidney failure
  • Referral with manifestations of an episode of acute pancreatitis or chronic pancreatitis
  • Use of antibiotics, antacids, and other medications that may interfere with the effects of somatostatin
  • History of previous angina, myocardial infarction, or cerebral ischemia within the past three months

研究者

相似试验

Octreotide and indomethacin in the prevention of... | 临床试验